Item | Property | Value | Comments |
---|
include | http://hl7.org/fhir/sid/cvx | | |
 Concept | | 54 | | Version: adenovirus, type 4 | |
 Concept | | 55 | | Version: adenovirus, type 7 | |
 Concept | | 82 | | Version: adenovirus, unspecified formulation | |
 Concept | | 24 | | Version: Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis | |
 Concept | | 19 | | Version: BCG | |
 Concept | | 27 | | Version: botulinum antitoxin | |
 Concept | | 26 | | Version: cholera, unspecified formulation | |
 Concept | | 29 | | Version: CMVIG | |
 Concept | | 56 | | Version: dengue fever tetravalent | |
 Concept | | 12 | | Version: diphtheria antitoxin | |
 Concept | | 28 | | Version: DT (pediatric) | |
 Concept | | 20 | | Version: DTaP | |
 Concept | | 106 | | Version: DTaP, 5 pertussis antigens | |
 Concept | | 107 | | Version: DTaP, unspecified formulation | |
 Concept | | 110 | | Version: DTaP-Hep B-IPV | |
 Concept | | 50 | | Version: DTaP-Hib | |
 Concept | | 120 | | Version: DTaP-Hib-IPV | |
 Concept | | 130 | | Version: DTaP-IPV | |
 Concept | | 22 | | Version: DTP-Hib | |
 Concept | | 102 | | Version: DTP-Hib-Hep B | |
 Concept | | 57 | | Version: hantavirus | |
 Concept | | 52 | | Version: Hep A, adult | |
 Concept | | 83 | | Version: Hep A, ped/adol, 2 dose | |
 Concept | | 84 | | Version: Hep A, ped/adol, 3 dose | |
 Concept | | 31 | | Version: Hep A, pediatric, unspecified formulation | |
 Concept | | 85 | | Version: Hep A, unspecified formulation | |
 Concept | | 104 | | Version: Hep A-Hep B | |
 Concept | | 30 | | Version: HBIG | |
 Concept | | 42 | | Version: Hep B, adolescent/high risk infant | |
 Concept | | 43 | | Version: Hep B, adult | |
 Concept | | 44 | | Version: Hep B, high-dosage, dialysis or IC | |
 Concept | | 45 | | Version: Hep B, unspecified formulation | |
 Concept | | 58 | | Version: Hep C | |
 Concept | | 59 | | Version: Hep E | |
 Concept | | 60 | | Version: herpes simplex 2 | |
 Concept | | 46 | | Version: Hib (PRP-D) | |
 Concept | | 47 | | Version: Hib (HbOC) | |
 Concept | | 48 | | Version: Hib (PRP-T) | |
 Concept | | 49 | | Version: Hib (PRP-OMP) | |
 Concept | | 17 | | Version: Hib, unspecified formulation | |
 Concept | | 51 | | Version: Hib-Hep B | |
 Concept | | 61 | | Version: HIV | |
 Concept | | 118 | | Version: HPV, bivalent | |
 Concept | | 62 | | Version: HPV, quadrivalent | |
 Concept | | 86 | | Version: IG | |
 Concept | | 87 | | Version: IGIV | |
 Concept | | 14 | | Version: IG, unspecified formulation | |
 Concept | | 111 | | Version: Influenza, live, trivalent, intranasal, PF | |
 Concept | | 15 | | Version: influenza, split (incl. purified surface antigen) | |
 Concept | | 16 | | Version: influenza, whole | |
 Concept | | 88 | | Version: influenza, unspecified formulation | |
 Concept | | 123 | | Version: influenza, H5N1-1203 | |
 Concept | | 10 | | Version: IPV | |
 Concept | | 89 | | Version: polio, unspecified formulation | |
 Concept | | 39 | | Version: Japanese encephalitis SC | |
 Concept | | 63 | | Version: Junin virus | |
 Concept | | 64 | | Version: leishmaniasis | |
 Concept | | 65 | | Version: leprosy | |
 Concept | | 66 | | Version: Lyme disease | |
 Concept | | 94 | | Version: MMRV | |
 Concept | | 67 | | Version: malaria | |
 Concept | | 68 | | Version: melanoma | |
 Concept | | 32 | | Version: meningococcal MPSV4 | |
 Concept | | 103 | | Version: meningococcal C conjugate | |
 Concept | | 114 | | Version: meningococcal MCV4P | |
 Concept | | 108 | | Version: meningococcal ACWY, unspecified formulation | |
 Concept | | 69 | | Version: parainfluenza-3 | |
 Concept | | 11 | | Version: pertussis | |
 Concept | | 23 | | Version: plague | |
 Concept | | 33 | | Version: pneumococcal polysaccharide PPV23 | |
 Concept | | 100 | | Version: pneumococcal conjugate PCV 7 | |
 Concept | | 109 | | Version: pneumococcal, unspecified formulation | |
 Concept | | 70 | | Version: Q fever | |
 Concept | | 18 | | Version: rabies, intramuscular injection | |
 Concept | | 40 | | Version: rabies, intradermal injection | |
 Concept | | 90 | | Version: rabies, unspecified formulation | |
 Concept | | 72 | | Version: rheumatic fever | |
 Concept | | 73 | | Version: Rift Valley fever | |
 Concept | | 34 | | Version: RIG | |
 Concept | | 119 | | Version: rotavirus, monovalent | |
 Concept | | 122 | | Version: rotavirus, unspecified formulation | |
 Concept | | 116 | | Version: rotavirus, pentavalent | |
 Concept | | 74 | | Version: rotavirus, tetravalent | |
 Concept | | 71 | | Version: RSV-IGIV | |
 Concept | | 93 | | Version: RSV-MAb | |
 Concept | | 38 | | Version: rubella/mumps | |
 Concept | | 76 | | Version: Staphylococcus bacterio lysate | |
 Concept | | 113 | | Version: Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | |
 Concept | | 115 | | Version: Tdap | |
 Concept | | 35 | | Version: tetanus toxoid, adsorbed | |
 Concept | | 112 | | Version: tetanus toxoid, unspecified formulation | |
 Concept | | 77 | | Version: Tick-borne encephalitis vaccine (non-US) | |
 Concept | | 13 | | Version: TIG | |
 Concept | | 95 | | Version: TST-OT tine test | |
 Concept | | 96 | | Version: TST-PPD intradermal | |
 Concept | | 97 | | Version: TST-PPD tine test | |
 Concept | | 98 | | Version: TST, unspecified formulation | |
 Concept | | 78 | | Version: tularemia vaccine | |
 Concept | | 91 | | Version: typhoid, unspecified formulation | |
 Concept | | 25 | | Version: typhoid, oral | |
 Concept | | 41 | | Version: typhoid, parenteral | |
 Concept | | 53 | | Version: typhoid, parenteral, AKD (U.S. military) | |
 Concept | | 101 | | Version: typhoid, ViCPs | |
 Concept | | 75 | | Version: Vaccinia (smallpox, mpox), live | |
 Concept | | 105 | | Version: vaccinia (smallpox) diluted | |
 Concept | | 79 | | Version: vaccinia immune globulin | |
 Concept | | 21 | | Version: varicella | |
 Concept | | 81 | | Version: VEE, inactivated | |
 Concept | | 80 | | Version: VEE, live | |
 Concept | | 92 | | Version: VEE, unspecified formulation | |
 Concept | | 36 | | Version: VZIG | |
 Concept | | 117 | | Version: VZIG (IND) | |
 Concept | | 37 | | Version: yellow fever live | |
 Concept | | 121 | | Version: zoster live | |
 Concept | | 998 | | Version: no vaccine administered | |
 Concept | | 999 | | Version: unknown | |
 Concept | | 99 | | Version: RESERVED - do not use | |
 Concept | | 133 | | Version: Pneumococcal conjugate PCV 13 | |
 Concept | | 134 | | Version: Japanese Encephalitis IM | |
 Concept | | 137 | | Version: HPV, unspecified formulation | |
 Concept | | 136 | | Version: Meningococcal MCV4O | |
 Concept | | 135 | | Version: Influenza, high-dose, trivalent, PF | |
 Concept | | 131 | | Version: typhus, historical | |
 Concept | | 132 | | Version: DTaP-IPV-HIB-HEP B, historical | |
 Concept | | 128 | | Version: Novel Influenza-H1N1-09, all formulations | |
 Concept | | 125 | | Version: Novel Influenza-H1N1-09, nasal | |
 Concept | | 126 | | Version: Novel influenza-H1N1-09, preservative-free | |
 Concept | | 127 | | Version: Novel influenza-H1N1-09 | |
 Concept | | 138 | | Version: Td (adult) | |
 Concept | | 139 | | Version: Td(adult) unspecified formulation | |
 Concept | | 140 | | Version: Influenza, split virus, trivalent, PF | |
 Concept | | 129 | | Version: Japanese Encephalitis, unspecified formulation | |
 Concept | | 141 | | Version: Influenza, split virus, trivalent, preservative | |
 Concept | | 142 | | Version: tetanus toxoid, not adsorbed | |
 Concept | | 143 | | Version: Adenovirus types 4 and 7 | |
 Concept | | 144 | | Version: influenza, seasonal, intradermal, preservative free | |
 Concept | | 145 | | Version: RSV-MAb (new) | |
 Concept | | 146 | | Version: DTaP,IPV,Hib,HepB | |
 Concept | | 147 | | Version: meningococcal MCV4, unspecified formulation | |
 Concept | | 148 | | Version: Meningococcal C/Y-HIB PRP | |
 Concept | | 149 | | Version: Influenza, live, quadrivalent, intranasal | |
 Concept | | 150 | | Version: Influenza, split virus, quadrivalent, PF | |
 Concept | | 151 | | Version: influenza nasal, unspecified formulation | |
 Concept | | 152 | | Version: Pneumococcal Conjugate, unspecified formulation | |
 Concept | | 153 | | Version: Influenza, MDCK, trivalent, PF | |
 Concept | | 154 | | Version: Hep A, IG | |
 Concept | | 155 | | Version: Influenza, recombinant, trivalent, PF | |
 Concept | | 156 | | Version: Rho(D)-IG | |
 Concept | | 157 | | Version: Rho(D) -IG IM | |
 Concept | | 158 | | Version: Influenza, split virus, quadrivalent, preservative | |
 Concept | | 159 | | Version: Rho(D) - Unspecified formulation | |
 Concept | | 160 | | Version: Influenza A monovalent (H5N1), ADJUVANTED-2013 | |
 Concept | | 801 | | Version: AS03 Adjuvant | |
 Concept | | 161 | | Version: Influenza, injectable,quadrivalent, preservative free, pediatric | |
 Concept | | 162 | | Version: meningococcal B, recombinant | |
 Concept | | 163 | | Version: meningococcal B, OMV | |
 Concept | | 164 | | Version: meningococcal B, unspecified | |
 Concept | | 165 | | Version: HPV9 | |
 Concept | | 166 | | Version: influenza, intradermal, quadrivalent, preservative free | |
 Concept | | 167 | | Version: meningococcal, unknown serogroups | |
 Concept | | 168 | | Version: Influenza, adjuvanted, trivalent, PF | |
 Concept | | 169 | | Version: Hep A, live attenuated | |
 Concept | | 170 | | Version: DTAP/IPV/HIB - non-US | |
 Concept | | 171 | | Version: Influenza, MDCK, quadrivalent, PF | |
 Concept | | 172 | | Version: cholera, WC-rBS | |
 Concept | | 173 | | Version: cholera, BivWC | |
 Concept | | 174 | | Version: cholera, live attenuated | |
 Concept | | 175 | | Version: Rabies - IM Diploid cell culture | |
 Concept | | 176 | | Version: Rabies - IM fibroblast culture | |
 Concept | | 177 | | Version: PCV10 | |
 Concept | | 178 | | Version: OPV bivalent | |
 Concept | | 179 | | Version: OPV ,monovalent, unspecified | |
 Concept | | 180 | | Version: tetanus immune globulin | |
 Concept | | 181 | | Version: anthrax immune globulin | |
 Concept | | 182 | | Version: OPV, Unspecified | |
 Concept | | 183 | | Version: Yellow fever vaccine live - alt | |
 Concept | | 184 | | Version: Yellow fever, unspecified | |
 Concept | | 185 | | Version: Influenza, recombinant, quadrivalent, PF | |
 Concept | | 186 | | Version: Influenza, MDCK, quadrivalent, preservative | |
 Concept | | 187 | | Version: zoster recombinant | |
 Concept | | 188 | | Version: zoster, unspecified formulation | |
 Concept | | 189 | | Version: HepB-CpG | |
 Concept | | 190 | | Version: Typhoid conjugate vaccine (TCV) | |
 Concept | | 191 | | Version: meningococcal A polysaccharide (non-US) | |
 Concept | | 192 | | Version: meningococcal AC polysaccharide (non-US) | |
 Concept | | 193 | | Version: Hep A-Hep B, pediatric/adolescent | |
 Concept | | 194 | | Version: Influenza, Southern Hemisphere | |
 Concept | | 195 | | Version: DT, IPV adsorbed | |
 Concept | | 196 | | Version: Td, adsorbed, preservative free, adult use, Lf unspecified | |
 Concept | | 197 | | Version: Influenza, high-dose, quadrivalent, PF | |
 Concept | | 200 | | Version: influenza, Southern Hemisphere, pediatric, preservative free | |
 Concept | | 201 | | Version: Influenza, Southern Hemisphere, quadrivalent, PF | |
 Concept | | 202 | | Version: influenza, Southern Hemisphere, quadrivalent, with preservative | |
 Concept | | 198 | | Version: DTP-hepB-Hib Pentavalent Non-US | |
 Concept | | 203 | | Version: meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | |
 Concept | | 205 | | Version: Influenza, adjuvanted, quadrivalent, PF | |
 Concept | | 206 | | Version: Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection | |
 Concept | | 207 | | Version: COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | |
 Concept | | 208 | | Version: COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | |
 Concept | | 213 | | Version: SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | |
 Concept | | 210 | | Version: COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL | |
 Concept | | 212 | | Version: COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | |
 Concept | | 204 | | Version: Ebola Zaire vaccine, live, recombinant, 1mL dose | |
 Concept | | 214 | | Version: Ebola, unspecified | |
 Concept | | 211 | | Version: COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | |
 Concept | | 500 | | Version: COVID-19 Non-US Vaccine, Product Unknown | |
 Concept | | 501 | | Version: COVID-19 IV Non-US Vaccine (QAZCOVID-IN) | |
 Concept | | 502 | | Version: COVID-19 IV Non-US Vaccine (COVAXIN) | |
 Concept | | 503 | | Version: COVID-19 LAV Non-US Vaccine (COVIVAC) | |
 Concept | | 504 | | Version: COVID-19 VVnr Non-US Vaccine (Sputnik Light) | |
 Concept | | 505 | | Version: COVID-19 VVnr Non-US Vaccine (Sputnik V) | |
 Concept | | 506 | | Version: COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology | |
 Concept | | 507 | | Version: COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences) | |
 Concept | | 508 | | Version: COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) | |
 Concept | | 509 | | Version: COVID-19 PS Non-US Vaccine (EpiVacCorona) | |
 Concept | | 510 | | Version: COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) | |
 Concept | | 511 | | Version: COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) | |
 Concept | | 215 | | Version: Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF | |
 Concept | | 216 | | Version: Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | |
 Concept | | 219 | | Version: COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose | |
 Concept | | 217 | | Version: COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | |
 Concept | | 218 | | Version: COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | |
 Concept | | 220 | | Version: HepB recombinant, 3-antigen, Al(OH)3 | |
 Concept | | 221 | | Version: COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose | |
 Concept | | 222 | | Version: Tick-borne encephalitis, unspecified | |
 Concept | | 223 | | Version: Tick-borne encephalitis, inactivated, PF, 0.25mL | |
 Concept | | 224 | | Version: Tick-borne encephalitis, inactivated, PF, 0.5mL | |
 Concept | | 225 | | Version: COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL | |
 Concept | | 226 | | Version: COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL | |
 Concept | | 512 | | Version: SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) | |
 Concept | | 513 | | Version: SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) | |
 Concept | | 514 | | Version: SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) | |
 Concept | | 515 | | Version: SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) | |
 Concept | | 516 | | Version: COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) | |
 Concept | | 517 | | Version: SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) | |
 Concept | | 227 | | Version: COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose | |
 Concept | | 228 | | Version: COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose | |
 Concept | | 229 | | Version: COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose | |
 Concept | | 301 | | Version: COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose | |
 Concept | | 300 | | Version: COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose | |
 Concept | | 230 | | Version: COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL | |
 Concept | | 518 | | Version: COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) | |
 Concept | | 519 | | Version: COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna | |
 Concept | | 520 | | Version: COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech | |
 Concept | | 521 | | Version: COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK | |
 Concept | | 231 | | Version: influenza, Southern Hemisphere, high-dose, quadrivalent | |
 Concept | | 303 | | Version: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF | |
 Concept | | 304 | | Version: Respiratory syncytial virus (RSV), unspecified | |
 Concept | | 305 | | Version: RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | |
 Concept | | 306 | | Version: RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months | |
 Concept | | 307 | | Version: RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months | |
 Concept | | 313 | | Version: COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | |
 Concept | | 308 | | Version: COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | |
 Concept | | 309 | | Version: COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | |
 Concept | | 310 | | Version: COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | |
 Concept | | 312 | | Version: COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | |
 Concept | | 311 | | Version: COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | |
 Concept | | 315 | | Version: Respiratory syncytial virus (RSV) MAB, unspecified | |
 Concept | | 314 | | Version: Respiratory syncytial virus (RSV) vaccine, unspecified | |
 Concept | | 316 | | Version: Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | |
 Concept | | 317 | | Version: Chikungunya live attenuated vaccine, 0.5 mL, PF | |
 Concept | | 318 | | Version: Anthrax, post-exposure prophylaxis | |
 Concept | | 319 | | Version: Anthrax vaccine, unspecified | |
 Concept | | 320 | | Version: Influenza, MDCK, trivalent, preservative | |
 Concept | | 321 | | Version: Influenza-avian, H5N8, monovalent, PF | |
 Concept | | 322 | | Version: Influenza-avian, H5N8, monovalent, preservative | |
 Concept | | 324 | | Version: Poliovirus, inactivated, fractional-dose (fIPV) | |
 Concept | | 323 | | Version: Influenza-avian, H5, unspecified formulation | |
 Concept | | 326 | | Version: RSV, mRNA, injectable, PF | |
 Concept | | 327 | | Version: Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF | |
 Concept | | 328 | | Version: Meningococcal oligosaccharide (MenACWY), (MenB), PF | |
 Concept | | 329 | | Version: Chikungunya, VLP, recombinant, 0.8 mL, PF | |
 Concept | | 330 | | Version: Dengue fever, unspecified | |
 Concept | | 331 | | Version: Influenza, Southern Hemisphere, trivalent, PF | |
 Concept | | 325 | | Version: Vaccinia (smallpox, mpox), unspecified | |
 Concept | | 332 | | Version: RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF | |
 Concept | | 333 | | Version: Influenza, live, trivalent, intranasal, self/caregiver admin, PF | |
 Concept | | 302 | | Version: COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose | |